| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | XMD11-85h | GDSC1000 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | decitabine:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.8 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | 0.034 | 0.8 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | -0.013 | 0.8 |